Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii

References

• Barbier F, Andremont A, Wolff M, et al. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med. 2013;19:216–228.
   PubMed Web of Science ®Google Scholar
• Abu-Salah T, Dhand R. Inhaled Antibiotic therapy for ventilator-associated tracheobronchitis and ventilator associated pneumonia: an update. Adv Ther. 2011;28:728–747.
   PubMed Web of Science ®Google Scholar
• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–1208.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–e111.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, et al. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Crit Care. 2016;20:221–231.
   PubMed Web of Science ®Google Scholar
• Garcia-Garmendia JL, Ortiz-Leyba K, Garnacho-Montero J, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis. 2001;33:939–946.
   PubMed Web of Science ®Google Scholar
• Chang SC, Chen YC, Luh KT, et al. In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood. Diagn Microbiol Infect Dis. 1995;23:105–110.
   PubMed Web of Science ®Google Scholar
• Schiffman DO. Evaluation of amikacin sulfate (Amikin). A new aminoglycoside antibiotic. JAMA 1977;238:1547–1550.
   PubMed Web of Science ®Google Scholar
• Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122:219–226.
   PubMed Web of Science ®Google Scholar
• Niederman MS, Chastre J, Corkery K, et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012;38:263–271.
   PubMed Web of Science ®Google Scholar
• Stass H, Willmann S, Wendl T. Risk assessment for amikacin Inhale in ICU patients using whole-body physiologically-based PK-models. In: 43rd Critical care congress, abstract P-926; 2014; San Francisco, CA.
   Google Scholar
• So W, Crandon JL, Hamada Y, et al. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem. J Antimicrob Chemother. 2016;71:428–423.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; approved standard, 13th ed. 2016. Wayne, PA: Clinical and Laboratory Standards Institute.
   Google Scholar
• McGann P, Courvalin P, Snesrud E, et al. Amplification of aminoglycoside resistance gene aphA1 in Acinetobacter baumannii results in tobramycin therapy failure. MBio 2014;5:e00915.
   PubMed Web of Science ®Google Scholar
• McGann P, Snesrud E, Ong AC, et al. War wound treatment complications due to transfer of an IncN plasmid harboring blaOXA-181 from Morganella morganii to CTX-M-27-producing ST131 Escherichia coli. Antimicrob Agents Chemother. 2015;59:3556–3562.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Sorgel F, Melnick D, et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2011;55:1606–1610.
   PubMed Web of Science ®Google Scholar
• Elkhaili H, Niedergang S, Pompei D, et al. High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B Biomed Appl. 1996;686:19–26.
   PubMed Web of Science ®Google Scholar
• Tärnberg M, Nilsson LE, Dowzicky MJ. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the tigecycline evaluation and surveillance trial (T.E.S.T.), 2010-2014. Int J Infect Dis. 2016;49:141–148.
   PubMed Web of Science ®Google Scholar
• Hagihara M, Housman ST, Nicolau DP, et al. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014;58:874–879.
   PubMed Web of Science ®Google Scholar
• Housman ST, Hagihara M, Nicolau DP, et al. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2013;68:2296–2304.
   PubMed Web of Science ®Google Scholar
• Lim TP, Ledesma KR, Chang KT, et al. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2008;52:2898–2904.
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Seifert H, Appelbaum PC. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2010;67:191–197.
   PubMed Web of Science ®Google Scholar
• Sheng WH, Wang JT, Li SY, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis. 2011;70:380–386.
   PubMed Web of Science ®Google Scholar
• Cha MK, Kang CI, Kim SH, et al. In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia. Antimicrob Agents Chemother. 2015;59:5834–5837.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Avial I, Pena I, Picazo JJ, et al. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents. 2015;46:616–621.
   PubMed Web of Science ®Google Scholar